Russ Conroy

The phase 3 TALAPRO-2 study met the primary end point of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations following treatment with a combination of talazoparib and enzalutamide.

Results from a phase 2 trial indicated that atezolizumab and bevacizumab yielded a significant duration of response in recurrent endometrial cancer.

Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.

Results from the phase 3 ATHENA-MONO study suggest that rucaparib could serve as a promising first-line maintenance treatment option in newly diagnosed ovarian cancer.

Results from the phase 3 CALLA trial indicated that durvalumab in combination with chemoradiotherapy did not yield a meaningful improvement in progression-free survival compared with chemoradiotherapy alone in high-risk locally advanced cervical cancer.

The Oncomine Dx Target Test was granted approval by the FDA as a companion diagnostic for RET fusion–positive thyroid cancer and RET fusion–positive non–small cell lung cancer.

Results from a post-hoc subgroup analysis of the phase 3 TROPiCS-02 study indicated that sacituzumab govitecan improved efficacy outcomes vs physician’s choice of treatment in HER2-low and HER2 immunohistochemistry 0, hormone receptor–positive metastatic breast cancer.

The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.

Findings from the phase 3 COSMIC-021 trial, comparing the effect of cabozantinib alone or in combination with atezolizumab vs docetaxel for advanced non–small cell lung cancer previously treated with immunotherapy, though promising, highlighted further need for randomized data to confirm the regimen’s benefit in the second-line setting, according to Joel W. Neal, MD, PhD.

The positive results from the phase 3 CheckMate76K trial suggest that recurrence-free survival may be improved following treatment with adjuvant nivolumab vs placebo in fully resected stage IIB/C melanoma.

Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.